How to Get Praluent (Alirocumab) in California

What Is Praluent and Why Would a California Doctor Prescribe It?

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors active, which pulls more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with HeFH or clinical ASCVD who need additional lowering of LDL cholesterol on top of diet and maximally tolerated statin therapy [1].

The clinical case for prescribing alirocumab in California is identical to the national standard because FDA labeling applies uniformly. In ODYSSEY OUTCOMES (N=18,924), patients with recent acute coronary syndrome who received alirocumab 75 to 150 mg every 2 weeks achieved a 15% relative reduction in the primary composite endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, compared with placebo, over a median follow-up of 2.8 years (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) [2]. That is the landmark evidence California prescribers cite when justifying a Praluent prescription.

California has approximately 750,000 adults living with familial hypercholesterolemia based on CDC population estimates and the estimated FH prevalence of 1 in 250 [3]. The majority remain undiagnosed or undertreated, which means the demand for PCSK9 inhibitor access in the state is substantial.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with very high-risk ASCVD whose LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable (Class IIa, Level A)" [4]. California cardiologists and internists apply this guideline directly.

Who Can Prescribe Praluent in California?

Any California-licensed prescriber with Schedule II prescribing authority can write a Praluent prescription. In practice, that includes MDs, DOs, nurse practitioners (NPs) with furnishing authority under Business and Professions Code Section 2836.1, and physician assistants (PAs) with physician supervision or, under AB 890 (2020), independent practice in certain settings [5].

Cardiologists write the majority of alirocumab prescriptions nationally because ASCVD management sits within their specialty. Endocrinologists and lipidologists prescribe it for FH. Primary care physicians, including those practicing through telehealth platforms, may prescribe alirocumab when the clinical picture is clear and documentation supports the indication.

The California Medical Board does not restrict PCSK9 inhibitor prescribing to a specific specialty. A telehealth NP or PA working under a supervising California-licensed physician may prescribe Praluent provided the clinical evaluation is adequate. The 2024 California Department of Managed Health Care telehealth parity regulations require that covered health plans reimburse telehealth visits for medication management at the same rate as in-person visits, removing a prior financial barrier to telehealth prescribing of specialty drugs [6].

What Labs and Workup Do You Need Before Getting Praluent in California?

A fasting lipid panel is the minimum required lab before a prescriber in California will write alirocumab. Most prior authorization forms also require documentation of a specific LDL-C value obtained while the patient is on maximally tolerated statin therapy.

The standard clinical workup includes a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C), a comprehensive metabolic panel to rule out secondary causes of hyperlipidemia such as hypothyroidism and nephrotic syndrome, and a thyroid-stimulating hormone level [7]. Liver function tests are not required before alirocumab specifically, though they are often drawn as part of the comprehensive metabolic panel for baseline purposes.

For FH diagnosis, most California lipidologists apply the Dutch Lipid Clinic Network (DLCN) criteria, which assign point scores based on personal and family history, physical findings, and LDL-C levels [8]. A score of 6 or higher establishes probable or definite FH and supports the alirocumab indication with payers.

Genetic testing for LDLR, APOB, or PCSK9 mutations is not required for FDA approval or most prior authorizations, but a positive result strengthens a Medi-Cal or commercial insurer prior authorization submission. Quest Diagnostics and LabCorp both offer FH gene panels with results in 10 to 14 business days, and both have California draw sites statewide.

The ACC/AHA pooled cohort equations calculator (available at tools.acc.org) can document 10-year ASCVD risk above 7.5%, which is often cited in prior authorization forms for patients with borderline or intermediate risk who also carry elevated LDL-C [9].

How to Get a Praluent Prescription Through Telehealth in California

California law explicitly permits telehealth prescribing of non-controlled medications following a valid patient-provider relationship established via synchronous audio-video or, in some circumstances, asynchronous store-and-forward communication [10]. Alirocumab is not a controlled substance, so there is no federal Ryan Haight Act barrier to telehealth prescribing.

The practical steps for a California resident seeking Praluent via telehealth are:

1. Schedule a synchronous video visit with a California-licensed telehealth provider who manages lipid disorders or cardiovascular risk.
2. Upload or fax recent lab results (fasting lipid panel dated within 6 months, current statin dose, and any prior lipid medication history) before the appointment.
3. During the visit, the clinician confirms the indication, documents LDL-C on maximally tolerated statin, and assesses cardiovascular history.
4. The prescriber submits the prior authorization to your insurance plan. Most platforms use electronic prior authorization (ePA) through CoverMyMeds or Surescripts.
5. If approved, the prescription is sent electronically to a specialty pharmacy. If denied, the prescriber initiates an appeal or peer-to-peer review.

Telehealth platforms operating in California and managing lipid disorders include HealthRX and comparable services. Response times for prior authorization in California average 5 to 7 business days for commercial plans under California Health and Safety Code Section 1367.01, which mandates a decision within 5 business days for standard requests [11].

How Prior Authorization for Praluent Works in California

Prior authorization (PA) is required by virtually every California payer before alirocumab will be dispensed. The core documentation elements are consistent across Anthem, Blue Shield of California, Health Net, Covered California plans, and Medi-Cal managed care organizations.

A standard California prior authorization submission for alirocumab requires: confirmed diagnosis (HeFH, HoFH, or established ASCVD by ICD-10 code), documented LDL-C on maximally tolerated statin (the threshold is typically 70 mg/dL for ASCVD patients and 100 mg/dL for FH patients without ASCVD), evidence that the patient has tried and failed or cannot tolerate a high-intensity statin, documentation of ezetimibe use or contraindication, and the proposed dose and frequency [12].

Medi-Cal fee-for-service covers alirocumab under the Medi-Cal Rx formulary with PA. The California Department of Health Care Services Medi-Cal formulary lists alirocumab under specialty tier requiring PA approval. Medi-Cal managed care plans (including LA Care, Partnership HealthPlan, and Inland Empire Health Plan) each have their own PA criteria aligned with DHCS guidance [13].

If the initial PA is denied, California insurers are required under SB 1083 to offer an expedited appeal when the denial poses risk to the enrollee's health. A cardiologist or lipidologist peer-to-peer call with the plan's medical director resolves the majority of denials. Published data from the American Journal of Managed Care show that peer-to-peer review overturns PCSK9 inhibitor denials in approximately 60% of cases [14].

The Praluent Copay Card program through Sanofi provides commercial insurance patients with copay assistance, reducing out-of-pocket cost to as low as $0 per month for eligible patients. Medi-Cal enrollees are not eligible for copay cards but may be eligible for the Sanofi Patient Assistance Program (PAP), which provides alirocumab at no cost to qualifying low-income patients [15].

Where to Fill a Praluent Prescription in California

Alirocumab requires cold-chain handling and is dispensed through specialty pharmacies rather than most retail chains. In California, the major specialty pharmacy options are:

Accredo (a Cigna specialty pharmacy subsidiary) ships to California addresses from licensed California-located or out-of-state facilities operating under California Board of Pharmacy oversight. CVS Specialty, Walgreens Specialty, and Optum Rx Specialty all serve California patients. Express Scripts Specialty Pharmacy and Diplomat Pharmacy are additional options accepted by many California plans.

Standard Praluent shipment within California arrives in 2 to 5 business days after prior authorization approval and pharmacy processing. The auto-injector pen ships refrigerated at 2 to 8 degrees Celsius with temperature monitors. Patients should not leave the package on a porch in direct sunlight, as heat exposure above 25 degrees Celsius for more than 30 days renders the product outside labeled storage conditions per the FDA prescribing information [1].

California 503A compounding pharmacies, regulated by the California State Board of Pharmacy, are licensed to compound alirocumab analogs for specific patients when a prescriber documents a legitimate medical need not met by the commercially available product. This is uncommon because the branded product is widely available, but the option exists for patients with documented allergies to an excipient in the branded formulation [16]. The FDA has not placed alirocumab on its 503B outsourcing facility bulk drug substances list, which limits large-scale compounding; 503A compounding for individual patients remains available under state board oversight.

Transferring a Praluent Prescription to California

Patients relocating to California from another state who already have a Praluent prescription can transfer it, but California law has specific requirements. A valid California prescription requires a California-licensed prescriber. Out-of-state prescriptions for non-controlled medications may be honored by California pharmacies at the pharmacist's discretion, but most specialty pharmacies require a California-licensed prescriber's order before continuing to ship to a California address [17].

The practical path is to establish care with a California-licensed provider (in-person or via telehealth) within 30 to 60 days of relocating. Bring the out-of-state prescriber's documentation, including prior LDL-C values, statin trial history, and any prior authorization approval letters. California prescribers can often reuse this documentation for a new prior authorization submission, which shortens the approval timeline to as little as 5 business days.

If the previous plan approved alirocumab and the patient is enrolling in a new California plan, the new payer will typically require its own prior authorization even if the indication is unchanged. Exception: Covered California plans that use standardized formulary templates under Health Net, Anthem, or Blue Shield may accept a continuation-of-therapy exception, which has a lower documentation bar than a new PA [18].

How Long Does It Take to Get Praluent After the First Appointment in California?

The timeline from first telehealth or in-person visit to first injection in California depends on how quickly prior authorization is resolved. A representative sequence looks like this:

Day 1: Video or in-person visit, prescription sent to specialty pharmacy with PA submitted same day. Days 2 to 7: PA decision (California law mandates 5 business days for standard requests). Days 7 to 10: Specialty pharmacy processes, ships, and delivers refrigerated product. First injection: Day 8 to 14 in the best-case scenario, Day 15 to 21 when PA requires one round of additional documentation.

The LDL-C reduction begins within 2 weeks of the first injection. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every 2 weeks reduced LDL-C by a mean of 61.0% from baseline at week 24, with reductions apparent as early as week 4 [19]. Cardiovascular event reduction in ODYSSEY OUTCOMES was most pronounced in the subgroup with baseline LDL-C of 100 mg/dL or higher, where the absolute risk reduction reached 3.9% over the trial period [2].

Monitoring After Starting Praluent in California

Repeat lipid panel testing at 4 to 8 weeks after initiation confirms response and guides dose titration. If LDL-C remains above 70 mg/dL on 75 mg every 2 weeks, the prescriber may increase to 150 mg every 2 weeks per the FDA label [1]. A subsequent lipid panel 8 to 12 weeks after dose adjustment confirms the new steady state.

The ACC/AHA 2022 guideline recommends monitoring fasting lipid panels at 4 to 12 weeks after initiation of any new lipid-lowering therapy and every 3 to 12 months thereafter [4]. Annual lipid panels are generally adequate once LDL-C is at goal and dose is stable.

Injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in ODYSSEY OUTCOMES [2]. Neurocognitive adverse events were evaluated in the EBBINGHAUS trial (N=1,204), which found no significant difference in cognitive function between alirocumab and placebo over 19 months of follow-up, measured by the Cambridge Neuropsychological Test Automated Battery [20]. These data matter because early post-market concerns about PCSK9 inhibitors and cognition led the FDA to require neurocognitive labeling language; the EBBINGHAUS data support reassurance.

California patients should register the auto-injector with the Praluent Support360 program, which provides injection training calls, refill reminders, and specialty pharmacy coordination. Support360 also connects patients with the Sanofi PAP if financial need arises mid-therapy.

Cost and Coverage Summary for California Patients

Alirocumab list price is approximately $6,600 per year for the 75 mg every 2 weeks regimen. Net cost to commercially insured California patients using the Sanofi copay card is as low as $0 per month (maximum benefit $150 per fill, 12 fills per year) [15]. Medi-Cal Rx covers alirocumab after prior authorization at no cost to the enrollee. Medicare Part D covers alirocumab at the specialty tier; patients in the Extra Help (LIS) program pay reduced cost-sharing.

A 2022 analysis in JAMA Cardiology estimated that at a net price of $5,850 per year, alirocumab reaches cost-effectiveness thresholds of $100,000 per quality-adjusted life year in patients with baseline LDL-C above 100 mg/dL and established ASCVD, which aligns with the California Technology Assessment Forum's willingness-to-pay threshold [21].